UroGen Pharma (URGN) Net Income towards Common Stockholders (2016 - 2025)
Historic Net Income towards Common Stockholders for UroGen Pharma (URGN) over the last 10 years, with Q3 2025 value amounting to -$33.3 million.
- UroGen Pharma's Net Income towards Common Stockholders fell 4086.51% to -$33.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$164.6 million, marking a year-over-year decrease of 4269.79%. This contributed to the annual value of -$126.9 million for FY2024, which is 2408.94% down from last year.
- According to the latest figures from Q3 2025, UroGen Pharma's Net Income towards Common Stockholders is -$33.3 million, which was down 4086.51% from -$49.9 million recorded in Q2 2025.
- UroGen Pharma's 5-year Net Income towards Common Stockholders high stood at -$21.9 million for Q3 2023, and its period low was -$49.9 million during Q2 2025.
- Over the past 5 years, UroGen Pharma's median Net Income towards Common Stockholders value was -$28.5 million (recorded in 2021), while the average stood at -$30.4 million.
- Per our database at Business Quant, UroGen Pharma's Net Income towards Common Stockholders skyrocketed by 1635.46% in 2021 and then tumbled by 4950.75% in 2025.
- UroGen Pharma's Net Income towards Common Stockholders (Quarter) stood at -$28.5 million in 2021, then dropped by 1.47% to -$28.9 million in 2022, then grew by 9.88% to -$26.0 million in 2023, then plummeted by 44.19% to -$37.5 million in 2024, then grew by 11.1% to -$33.3 million in 2025.
- Its last three reported values are -$33.3 million in Q3 2025, -$49.9 million for Q2 2025, and -$43.8 million during Q1 2025.